Now showing items 1-5 of 5

    • Cox-2 Inhibition Enhances the Activity of Sunitinib in Human Renal Cell Carcinoma Xenografts 

      Wang, Xiaoen; Zhang, L; O'Neill, A; Bahamon, B; Alsop, David C.; Mier, James W.; Goldberg, S. Nahum; Signoretti, Sabina; Atkins, M B; Wood, C G; Bhatt, Rupal Satish (Nature Publishing Group, 2013)
      Background: Sunitinib (Su), a tyrosine kinase inhibitor of VEGFR, is effective at producing tumour response in clear cell renal cell carcinoma (cRCC), but resistance to therapy is inevitable. As COX-2 is a known mediator ...
    • High Dose Intermittent Sorafenib Shows Improved Efficacy Over Conventional Continuous Dose in Renal Cell Carcinoma 

      Wang, Xiaoen; Zhang, Liang; Goldberg, S. Nahum; Bhasin, Manoj; Brown, Victoria; Alsop, David C.; Signoretti, Sabina; Mier, James W.; Atkins, Michael B.; Bhatt, Rupal Satish (BioMed Central, 2011)
      Background: Renal cell carcinoma (RCC) responds to agents that inhibit vascular endothelial growth factor (VEGF) pathway. Sorafenib, a multikinase inhibitor of VEGF receptor, is effective at producing tumor responses and ...
    • Increased Mobilisation of Circulating Endothelial Progenitors in von Hippel-Lindau Disease and Renal Cell Carcinoma 

      Zurita, A J; Norden-Zfoni, A; George, D; Heymach, J V; Bhatt, Rupal Satish; O'Neill, Allison Frances; Zhang, Liang; Wu, H.K.; Wen, Patrick Yung Chih; Sukhatme, Vikas Pandurang; Atkins, M.B. (Nature Publishing Group, 2011)
      Background: Circulating endothelial cells (CECs) are a candidate biomarker for monitoring angiogenesis in cancer. Circulating endothelial cell subsets are mobilised by angiogenic mediators. Because of the highly angiogenic ...
    • Inhibition of ALK1 signaling with dalantercept combined with VEGFR TKI leads to tumor stasis in renal cell carcinoma 

      Wang, Xiaoen; Solban, Nicolas; Khanna, Prateek; Callea, Marcella; Song, Jiaxi; Alsop, David C.; Pearsall, R. Scott; Atkins, Michael B.; Mier, James W.; Signoretti, Sabina; Alimzhanov, Marat; Kumar, Ravi; Bhasin, Manoj K.; Bhatt, Rupal S. (Impact Journals LLC, 2016)
      Treatment of metastatic renal cell carcinoma (mRCC) with agents that block signaling through vascular endothelial growth factor receptor 2 (VEGFR2) induces disease regression or stabilization in some patients; however, ...
    • Resistance of Renal Cell Carcinoma to Sorafenib Is Mediated by Potentially Reversible Gene Expression 

      Bhasin, Manoj; Schor-Bardach, Rachel; Collins, Michael P.; Zhang, Liang; Wang, Xiaoen; Panka, David Joel; Putheti, Prabhakar; Signoretti, Sabina; Alsop, David C.; Libermann, Towia Aron; Atkins, Michael B.; Mier, James W.; Goldberg, S. Nahum; Bhatt, Rupal Satish (Public Library of Science, 2011)
      Purpose: Resistance to antiangiogenic therapy is an important clinical problem. We examined whether resistance occurs at least in part via reversible, physiologic changes in the tumor, or results solely from stable genetic ...